These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11054151)

  • 1. Introduction: pramipexole: a novel dopamine agonist for the treatment of Parkinson's disease.
    de Yebenes JG
    Eur J Neurol; 2000 May; 7 Suppl 1():1-2. PubMed ID: 11054151
    [No Abstract]   [Full Text] [Related]  

  • 2. Pramipexole in the treatment of advanced Parkinson's disease.
    Möller JC; Oertel WH
    Eur J Neurol; 2000 May; 7 Suppl 1():21-5. PubMed ID: 11054155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
    Bennett JP; Piercey MF
    J Neurol Sci; 1999 Feb; 163(1):25-31. PubMed ID: 10223406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pramipexole for Parkinson's disease.
    Ting RM; Force RW
    J Fam Pract; 1998 Jan; 46(1):19-20. PubMed ID: 9451363
    [No Abstract]   [Full Text] [Related]  

  • 5. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DA agonists -- non-ergot derivatives: pramipexole: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S93-7. PubMed ID: 12211148
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
    J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease.
    Künig G; Pogarell O; Möller JC; Delf M; Oertel WH
    Clin Neuropharmacol; 1999; 22(5):301-5. PubMed ID: 10516884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The initial drug treatment of older patients with Parkinson's disease - consider an agonist, but don't demonise dopa.
    MacMahon DG
    Age Ageing; 2003 May; 32(3):244-5. PubMed ID: 12720606
    [No Abstract]   [Full Text] [Related]  

  • 12. Pramipexole and ropinirole for Parkinson's disease.
    Med Lett Drugs Ther; 1997 Nov; 39(1014):109-10. PubMed ID: 9398824
    [No Abstract]   [Full Text] [Related]  

  • 13. Dopamine agonists in early therapy for Parkinson disease: promise and problems.
    Tanner CM
    JAMA; 2000 Oct; 284(15):1971-3. PubMed ID: 11035895
    [No Abstract]   [Full Text] [Related]  

  • 14. Ropinirole and pramipexole, the new agonists.
    Hobson DE; Pourcher E; Martin WR
    Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S27-33. PubMed ID: 10451757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current advances in Parkinson's disease.
    Ball J
    Trends Neurosci; 2001 Jul; 24(7):367-9. PubMed ID: 11467283
    [No Abstract]   [Full Text] [Related]  

  • 16. Pramipexole-treated Parkinson's disease during pregnancy.
    Mucchiut M; Belgrado E; Cutuli D; Antonini A; Bergonzi P
    Mov Disord; 2004 Sep; 19(9):1114-5. PubMed ID: 15372610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramipexole in patients with early Parkinson's disease.
    Hubble JP; Koller WC; Cutler NR; Sramek JJ; Friedman J; Goetz C; Ranhosky A; Korts D; Elvin A
    Clin Neuropharmacol; 1995 Aug; 18(4):338-47. PubMed ID: 8665547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine agonists and neuroprotection in Parkinson's disease.
    Schapira AH
    Eur J Neurol; 2002 Nov; 9 Suppl 3():7-14. PubMed ID: 12464116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of pramipexole and its clinical utility in Parkinson's disease.
    Biglan KM; Holloway RG
    Expert Opin Pharmacother; 2002 Feb; 3(2):197-210. PubMed ID: 11829733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
    JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.